BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
BioXcel Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -6054.7%. For fiscal 2025 it was -7860.0%, against -2967.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -7860.0% | −4892.4 |
| FY2024 | Dec 31, 2024 | -2967.6% | +9480.4 |
| FY2023 | Dec 31, 2023 | -12448.0% | +30124.0 |
| FY2022 | Dec 31, 2022 | -42572.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -5600.5% | +7609.5 |
| Q1 FY2026 | Mar 31, 2026 | -4962.6% | +1048.7 |
| Q4 FY2025 | Dec 31, 2025 | -4016.4% | −1149.5 |
| Q3 FY2025 | Sep 30, 2025 | -14518.4% | −7372.1 |
| Q2 FY2025 | Jun 30, 2025 | -13210.0% | −11643.3 |
| Q1 FY2025 | Mar 31, 2025 | -6011.3% | −1859.6 |
| Q4 FY2024 | Dec 31, 2024 | -2866.9% | +2419.0 |
| Q3 FY2024 | Sep 30, 2024 | -7146.3% | +7017.1 |
| Q2 FY2024 | Jun 30, 2024 | -1566.7% | +9902.5 |
| Q1 FY2024 | Mar 31, 2024 | -4151.7% | +20701.7 |
| Q4 FY2023 | Dec 31, 2023 | -5285.9% | +16938.5 |
| Q3 FY2023 | Sep 30, 2023 | -14163.3% | +14296.5 |
| Q2 FY2023 | Jun 30, 2023 | -11469.1% | – |
| Q1 FY2023 | Mar 31, 2023 | -24853.4% | – |
| Q4 FY2022 | Dec 31, 2022 | -22224.4% | – |
| Q3 FY2022 | Sep 30, 2022 | -28459.9% | – |
See a number that looks wrong?